Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.54 |
| ▸ | MLYCD | O95822 | 8/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25171472 | 0.85 | PDK2 (0.52) | PDK2DRD2KDM4EPOLBL3MBTL1 | |
| SCHEMBL27174665 | 0.84 | PDK2 (0.56) | PDK2KAT6AKAT5KDM4EPOLB | |
| SCHEMBL12745032 | 0.84 | PDK2 (0.56) | PDK2KAT6AKAT5KDM4EPOLB | |
| SCHEMBL2432345 | 0.83 | MAPT (0.59) | PDK2DRD2KDM4EL3MBTL1 | |
| SCHEMBL21601541 | 0.82 | PDK2 (0.54) | PDK2DRD2KDM4EPOLBL3MBTL1 | |
| SCHEMBL8257865 | 0.82 | PDK2 (0.54) | PDK2KAT6AKAT5KDM4EPOLB | |
| SCHEMBL7632127 | 0.82 | KDM4E (0.52) | MLYCDDRD2KDM4EPOLB | |
| SCHEMBL21601216 | 0.81 | PDK2 (0.53) | PDK2KAT6AKAT5KDM4EPOLB | |
| SCHEMBL991922 | 0.81 | PDK2 (0.53) | PDK2DRD2GPR119KAT6AKAT5 | |
| SCHEMBL8250703 | 0.81 | PDK2 (0.53) | PDK2KDM4EPOLBL3MBTL1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347568-A1 | HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240092757-A1 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | THE SCRIPPS RESEARCH INSTITUTE | 2024-03-21 | — | — | US | disclosed |
| WO-2022251533-A1 | HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | PROTEGO BIOPHARMA, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092757-A1 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | XBP1, HSPA5, DNAJC10 | PDK2 933/4885MLYCD 988/4885DRD2 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.